TrialBlood2015

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.

Thomas E Witzig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.